Navigation Links
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Date:11/23/2009

he first TPH inhibitor ever to be evaluated in human clinical trials for the treatment of IBS. In Phase 1 clinical trials, all dose levels of the drug were well tolerated, and no dose-limiting toxicities were observed. LX1031 was also shown to reduce levels of urinary 5-HIAA, a biomarker of serotonin production.

LX1031 is being developed in collaboration with Symphony Capital LLC.

About Irritable Bowel Syndrome

Irritable bowel syndrome is a disorder most commonly characterized by cramping, abdominal pain, bloating, constipation or diarrhea. According to the International Foundation for Functional Gastrointestinal Disorders, IBS affects between 25 and 45 million people in the United States. Symptoms of IBS are believed to be mediated through serotonin, which has been shown to play an important role in modulating motility and signaling feelings of GI discomfort.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's plans for further clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
2. Lexicon Announces Completion of Public Offering of Common Stock
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
5. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... PLAINFIELD, N.J. , Aug. 20, 2014 PTC Therapeutics, ... will participate at two upcoming investor conferences: - ... Seasons Hotel in Boston on Wednesday, ... Biotech Conference at The Mandarin Oriental Boston on Thursday, September ... present a company update at the Bank of America Merrill ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Personal Accident and ... Opportunities to 2018 ... provides in depth market analysis, information and ... health insurance segment, including: - The French ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportbuyer.com has added ... Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... in US$ Million by the following Product Segments: Implantable/Internal ... comprehensive analytics for the US, Canada ... , Asia-Pacific , ...
Breaking Medicine Technology:PTC Therapeutics to Participate at Upcoming Investor Conferences 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13
(Date:8/20/2014)... study of chronic users of codeine-containing cough syrups ... brain white matter and associates these changes with ... used diffusuion tensor imaging (DTI) (an MR imaging ... white matter integrity of chronic CCS users. Deficits ... including the inferior fronto-occipital fasciculus, which other studies ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... Barbara Bronson Gray HealthDay ... Although it,s extremely rare, colds, flu and other minor ... risk for stroke in children, a new study suggests. ... stroke in the United States, said Dr. Heather Fullerton, lead ... pediatrics at the University of California, San Francisco Benioff Children,s ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... avoid a condition that causes a life-threatening irregular heartbeat, a ... 10 percent lower risk of developing atrial fibrillation, compared to ... 20 issue of the Journal of the American Heart ... heart rhythm disorder even if they were obese, the study ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
... WHAT: , Go Red ... Broadway,s Tony Award-winning best musical In The Heights, kicks off,National ... WHO: , Go Red ... and inspiring others with their actions. Latinas who,share their stories ...
... Pa., Feb. 4 Kensey Nash Corporation (Nasdaq: ... solutions and technologies for a wide range of medical procedures, ... and Portfolio Manager of Ramius LLC, from its Board of ... 2007 and was a member of the Corporate Governance and ...
... of complete solutions for the analysis of Next Generation ... Biology Laboratory (EMBL) installed a Genomatix Mining Station and ... These systems deliver the only complete and integrated analysis ... by the sequencer, to a molecular level understanding of ...
... Daily Requirement of Vitamin EPARAMUS, N.J., Feb. 4 Smart ... it will launch Smart Balance(TM) Milk in supermarkets in the ... during the first quarter of 2009. Smart Balance(TM) Milk, ... Georgia, tastes rich and creamy, is low in saturated fat ...
... parents and children affected by the State Children,s Health Insurance ... final House vote on the bill, which President Obama will ... and answer to a reporter,s question:"This is a very special ... the Congress of the United States. Here we have our ...
... the leader in disease prevention services, announced today that ... CEO, and Fred Goldstein, President -- will speak at ... held February 9-11 in New York City. This ... participate in this exclusive conference for the world,s health ...
Cached Medicine News:Health News:Go Red Corazon(R) 'Que nos dice el corazon?' National Casting Call Event 2Health News:Kensey Nash Announces Director Resignation 2Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 2Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 3Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3Health News:Pelosi: 'Today is a Very Special Day for Us in the House; We Are Going to Help 11 Million Children' 2Health News:U.S. Preventive Medicine(R) Executives to Present at 2009 UBS Global Healthcare Services Conference 2
... produced in the adrenal cortex and, to ... serves as a precursor in testosterone and ... activity, estimated at ~10% that of testosterone ... in adult women, DHEA is an important ...
... Inovise Medicals AUDICOR is the first, ... professionals worldwide quickly rule-in cardiac dysfunction ... syndrome, and other high-risk cardiac conditions. ... existing workflow, AUDICOR products enable clinicians ...
... is produced primarily by 5-monodeioination of thyroxine ... gland, T3 production occurs at a rate ... T4. Release of T3 from the thyroid ... as compared to 80-100 micrograms/day for T4. ...
... Hormone Binding Protein (GHBP) is the soluble, extra-cellular ... is an integral component of the growth hormone-insulin-like ... species, it is either a cleavage product of ... the GH receptor gene. Growth Hormone receptor ...
Medicine Products: